Processing

Please wait...

Settings

Settings

Goto Application

1. US20060172346 - Methods of designing and producing novel compounds having improved binding affinity for CD154 or other trimeric proteins

Office
United States of America
Application Number 11317536
Application Date 23.12.2005
Publication Number 20060172346
Publication Date 03.08.2006
Publication Kind A1
IPC
G01N 33/567
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
566using specific carrier or receptor proteins as ligand binding reagent
567utilising isolate of tissue or organ as binding agent
C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Applicants ZHENG ZHONGLI
TAYLOR FREDERICK R
BENJAMIN CHRISTOPHER D
HSU YEN-MING
Inventors Zheng Zhongli
Taylor Frederick R.
Benjamin Christopher D.
Hsu Yen-Ming
Agents FISH &; NEAVE IP GROUP;ROPES &; GRAY LLP
Priority Data US0127360 31.08.2001 WO
Title
(EN) Methods of designing and producing novel compounds having improved binding affinity for CD154 or other trimeric proteins
Abstract
(EN)

The present invention relates to methods for designing and producing novel CD40:CD154 binding interrupter compounds and methods using these compounds to treat conditions associated with inappropriate CD154 activation in a subject. This invention also relates to novel methods for screening candidate compounds for the properties of specifically binding CD154 and interrupting CD40:CD154 interaction. This invention further relates to methods of improving the binding affinity, or the ability to block CD40/CD154 interaction, of a synthetic molecule for a trimeric protein, such as CD154. These methods comprise converting a first synthetic molecule that cannot promote lattice or aggregate formation of its target trimeric protein to a second synthetic molecule that can promote lattice or aggregate formation of its target trimeric protein. This invention also relates to a two-dimensional lattice or aggregate comprising a plurality of trimeric CD154 on a cell surface or in solution, wherein the lattice or aggregate is formed by bivalent anti-CD154 antibodies associated with trimeric CD154 molecules.